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Introduction: Lynch syndrome (LS) is an autosomal dominant condition and is the most 
common cause of inherited colorectal cancer (CRC), contributing to approximately 3%-5% of 
newly diagnosed cases of colorectal malignancy. LS affected individuals bear 18% – 53% 
lifetime risk for development of CRC. The only therapeutic approach to prevent development 
of CRC among individuals with LS is periodic colonoscopic screening for detection and 
removal of adenomas and polyps, which are the precursors for cancer. Despite being the 
current gold standard, and accounting for all other variables (such as experience of the 
physician), conventional colonoscopy has been known to sometimes miss detecting 
adenomas/polyps, specifically those present in the folds of the colonic mucosa and on the 
inner luminal wall of the colonic flexures. EndoRings™ assisted colonoscopy has therefore 
been developed to improve colonoscopy outcomes in terms of enhancing adenoma detection 
rates (ADR)/polyp detection rates (PDR) and involves flexible silicone rings mechanically 
stretching the colonic folds and thus enhancing total colon visualisation.
Objectives: The present study aims to primarily investigate the efficacy of EndoRings™ 
assisted colonoscopy compared to traditional colonoscopy in terms of ADR/PDR in a known 
cohort of individuals with LS in a South African setting. 
Methods: The study was conducted as a cross-sectional randomised controlled trial.
Individuals from the Northern Cape province of South Africa with LS were enrolled into the 
study during our Annual Northern Cape Colonoscopy Outreach trip for the year 2015. A total 
of 54 individuals (per-protocol) were included in the study and randomised blindly using
computer randomisation into a control arm undergoing standard colonoscopy (n=27) and a
study arm undergoing EndoRings™-assisted colonoscopy (n=27). Number of polyps detected 
(the primary outcome) along with a set of secondary outcomes was recorded in real time on 
data sheets for each individual and statically analysed using IPython. 
Results: The female to male ratio in the EndoRings™ group was 19:8 versus 15:12 in the 
standard colonoscopy group (P = 0.40) whereas the mean age of patients was 43.98±15.27 
years and 44.26±14.67 years (P = 0.05) respectively. The average number of polyps detected 
in the EndoRings™ group was 1.4 versus 0.9 in the non-EndoRings™ group (P = 0.60). 
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Conclusion: The present study outcomes observed comparable ADR/PDR in EndoRings™ 
assisted versus standard colonoscopy with no statistically significant difference. This result 
may be due to the study’s limitations (small sample size) and design. Though no statistically 
significant conclusions could be reached, EndoRings™ assisted colonoscopy was perceived 
as being helpful in terms of increasing total colonic visualisation and allowing better scope 
stabilisation during interventions. Comparable intubation times, withdrawal times, total 
procedure times and similar complication rates were observed in both study arms. Although 
this study demonstrated non-inferiority of EndoRings™ compared to standard colonoscopy, 
further studies with a larger sample size in an easily accessible population over a longer study 
period are recommended. 
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Chapter 1: Introduction and Literature review. 
 
1.1 Search methods. 
For this literature review and for the entirety of this thesis a relevant literature search was 
performed using PubMed, PubMed Central, Medical Subject Headings (MeSH), and 
UpToDate databases. All abstracts and full texts yielding from the search terms were used, 
provided they were in English. Some South African articles were obtained directly from the 
author concerned. Internal citations and references within the initial search articles were also 
sourced. 
1.2 Colorectal cancer. 
1.2.1 Incidence and epidemiology. 
Colorectal cancer (CRC) is a major cause of morbidity and mortality [1]. Globally it accounts 
for approximately 10% of all cancers [2,3]. Worldwide CRC is the 3rd most common cancer 
in men and 2nd most common in women, with 1.4 million new cases and almost 694,000 
deaths estimated to have occurred in 2012 [4]. According to GLOBOCAN, the reported 
incidence in western countries, or countries following a western lifestyle is significantly 
higher than in most African and South Asian countries [5]. However, trends in CRC 
incidence and mortality are reversing. In economically developed nations, incidence and 
mortality are currently on a decline, whilst in economically underdeveloped nations an 
uptrend is emerging [9]. Another worrying development is an increase in the incidence of 
young (<40 years) CRC. This phenomenon is occurring globally but is much more noticeable 
in the Middle Eastern and South and East Asian countries [9]. 
Risk factors for developing CRC can broadly be classified as environmental or inherited. 
Advanced age, lower socio-economic status, modifiable behaviors such as lack of exercise, 
smoking, poor diet, obesity, and a lack of a national screening program are all important risk 
factors [6-8]. 
In 2013 (latest data available), the South African National Cancer Registry reported the 
number of new cases of CRC diagnosed in South Africa as 1906 for men and 1542 for 
women. This translates to 5.3% and 4.2% of all cancers at age standardized incidence 




CRC present in three distinct patterns, sporadic, familial or hereditary. Sporadic CRC is the 
most common (60-70%) and occurs in individuals with no prior family history. 
Aetiologically these tumors are thought to be caused by modifiable environmental, dietary, 
behavioral risk factors as well as non-modifiable factors such as advanced age (>50 years) 
and sex [11]. 
Familial CRC, the 2nd most common (25%) is the least well understood and is not associated 
with any identifiable gene. Individuals have a positive family history, but the pattern is not 
entirely consistent with the hereditary syndromes. First degree family members of affected 
individuals are at two to three times greater risk than normal of developing CRC. The risk 
also increases if multiple first-degree relatives are affected or if the index case was less than 
50 years of age at diagnosis [12]. Familial CRC type X is a good example that has all the 
clinical criteria of Lynch syndrome (LS) but as yet no identifiable germline mutation [13]. 
Hereditary CRC (10%) has two main tumor variants that are distinguished by the propensity 
to develop a vast number of adenomatous polyps or not. The polyp forming variants include 
familial adenomatous polyposis (FAP) and its variants (attenuated FAP, MYH-associated 
FAP), MUTYH-associated polyposis (MAP) and various hamartomatous polyposis 
syndromes such as Peutz-Jeghers, juvenile polyposis and Cowden syndrome [14]. LS is the 
second variant, in which the affected individuals do not develop polyposis and only a few to 
no polyps may be identified. These hereditary conditions incur a very high risk of developing 
CRC, with almost 90-100% developing cancer in FAP and 50-70% in individuals with LS 
during their lifetime. 
 
1.2.3 Genetics. 
Our understanding of the molecular events involved in the development of CRC is greater 
than for other solid tumors. Germline mutations are involved in the development of the 
inherited syndromes, while a stepwise accumulation of somatic mutations is responsible for 
most sporadic cases resulting in a normal cell becoming malignant. Mostly CRCs develop 
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from mutations, suppression, deletions, overexpression, altered deoxyribonucleic acid (DNA) 
methylation, gene rearrangements, amplifications and deletions of a limited number of genes. 
The genes usually implicated are the adenomatous polyposis coli (APC), kRAS oncogene 
(kRAS), tumor protein 53 (p53), mismatch repair genes (MMR) MSH2 and MLH1 and more 
recently the deleted in colon cancer (DCC), SMAD4, and SMAD2 genes [15]. Development 
of CRC has been attributed to the breakdown of signaling pathways that are otherwise 
responsible for normal regulation of cellular function. These pathways include the following: 
 
The adenoma-carcinoma sequence pathway: Normally, intestinal cells are continuously 
lost and replaced by apoptosis and exfoliation into the intestinal lumen. New cells originate at 
the intestinal crypt base and progress towards the lumen at which time proliferation of cells 
ceases and they differentiate into their final form [16]. Most CRCs rise from adenomas 
(adenomatous polyps) in the colon that over time, due to stepwise disruption of the normal 
mechanisms, lead to dysplasia and ultimately carcinoma formation as illustrated in Figure 1 
below. 
 
Figure 1. A genetic model for colorectal tumourigenesis [17] 
LOH: loss of heterozygosity; DCC: deleted in colon cancer gene; APC: adenomatous 
polyposis coli gene; ACF: aberrant crypt foci; MMR: DNA mismatch repair enzyme [17]. 
 
In 1990, Fearon and Vogelstein provided molecular data to supplement the above concept. 
According to the Vogelstein model, germline or somatic mutations are necessary for 
carcinoma to develop, and it is the accumulation rather than the sequence of multiple genetic 
mutations that ultimately determines the biological behaviour of the tumour [16]. Germline 
mutations are responsible for inherited syndromes such as FAP and LS. Sporadic cancers 
generally occur due to a stepwise accumulation of multiple somatic mutations. Mutations in 
the APC gene occurs early in the tumorigenesis of both inherited and sporadic colorectal 
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cancers, while p53 tumour suppressor gene mutations generally occur later in the process 
[17]. 
 
Serrated polyp pathway: Although most CRCs are thought to develop through the 
adenoma-carcinoma sequence, recent evidence suggests the existence of an alternate pathway 
in which serrated polyps replace the traditional adenoma as the precursor lesion (Figure 2.) 
[18]. 
 
Figure 2. Serrated pathway versus classical pathway in tumourigenesis [19]. 
 
 
HPP: hyperplastic polyps, SSA: sessile serrated adenoma, TSA: traditional serrated adenoma 
[19]. 
 
Molecular tumourigenesis pathways: Currently three known molecular pathways leading 
to tumour formation exist. These are the chromosomal instability (CIN) pathway, the 
mutator- phenotype/DNA mismatch repair pathway and the hypermethylation phenotype 
hyperplastic/serrated polyp pathway [20]. Tumour formation via the CIN (APC) pathway 
results from "gain of function" mutations. This occurs due to activation of growth promoting 
oncogenes or secondary to diminished activity of tumour suppressor genes or apoptotic 
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pathways [16]. CIN tumours may be inherited (FAP) or sporadic, and are characterized by 
chromosomal abnormalities such as deletions, insertions, and loss of heterozygosity [16]. 
 
Inherited CRC such as LS characteristically progress through the mutator 
phenotype/mismatch repair pathway. This involves the dysfunction of DNA MMR enzymes, 
due to germline mutations in one of several different MMR genes, most commonly MLH1 or 
MSH2. Suppression of MMR genes result in accumulation of DNA errors in the genome. The 
accumulation of these abnormalities in short sequences of nucleotide bases may be repeated 
dozens to hundreds of times within the genome and are known as microsatellites. Therefore, 
tumours can phenotypically have high levels of microsatellite instability (MSI-H) or low 
levels of microsatellite instability (MSI-L). It should be noted that MSI -H occurs in 
approximately 15% of sporadic colorectal cancers as well, though in most of these cases the 
gene ‘silencing’ is not due to a MMR mutation but due to epigenetic reasons such as 
hypermethylation of the gene promoter for the MMR enzyme [21]. 
 
Lastly the hypermethylation phenotype (CIMP+) pathway involves epigenetic alterations 
such as DNA hypomethylation and loss of imprinting, as well as DNA hypermethylation 
resulting in silencing of certain genes [21-24]. CIMP+ colorectal tumours have a particularly 
high frequency of methylation of CpG islands. CpG islands consist of a cytosine [C] and a 
guanine [G] base linked by a phosphodiester bond. This defect results in hypermethylation of 
the promoter region of MMR enzymes especially MLH1 ultimately resulting in silencing of 
gene expression [21,25]. MSI-H, CIMP+ colorectal cancers present almost entirely with 
BRAF gene mutations and do not carry mutations in kRAS [26-28]. Lynch-related CRCs 
present only with kRAS and not BRAF mutations [26,27]. Tumours with BRAF mutations 
tend to have a worse prognosis than that which is typically associated with MSI-H tumours 
[29,30]. 
 
1.3 Lynch Syndrome. 
LS is an autosomal dominant condition characterised by germline mutation in one of the 
MMR genes (MLH1, MSH2, MSH6, PMS2) or the EPCAM gene. It is also commonly 
referred to as hereditary non-polyposis colorectal cancer (HNPCC) but there is a subtle 
difference between the two. While LS is characterised by gene mutations, HNPCC is defined 
clinically usually by family history and fulfilment of the Amsterdam criteria. LS is associated 
with an increased susceptibility to developing CRC cancer and extracolonic malignancies of 
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which endometrial cancer is most prevalent. LS accounts for approximately 3% of newly 
diagnosed CRCs and 3% of endometrial cancers [31]. It is estimated that 1 in 279 of the 
population carry mutations in DNA MMR genes [32]. In the Northern Cape region of South 
Africa, the incidence of colorectal cancer is relatively low at around 3-4/100000 [33]. Here 
10.5% of colorectal cancers were found to harbour a MMR gene mutation. This is 




The following MMR genes are involved [31]: 
 
● MLH1, on chromosome 3p22.2, mutated in 37%. 
 
● MSH2, on chromosome 2p21-16, mutated in 41%. 
 
● MSH6, on chromosome 2p16.3, mutated in 13%. 
 
● PMS2, on chromosome 7p22.1, mutated in 9%. 
 
In normal DNA replication the role of the MMR system is to preserve genomic integrity by 
correcting base substitution and small insertion-deletion mismatches. This is achieved 
through coordinated function of different gene products. Two heterodimer protein complexes, 
MutS-alpha and MutS-beta are responsible for the recognition of base pair mismatches. 
MutS-alpha is a MSH2 and MSH6 heterodimer where as MutS-beta is a heterodimer of 
MSH2/MSH3 [35]. Three heterodimer pairs termed MutL-alpha, MutL-beta, and MutL- 
gamma are responsible for the repair component of the MMR system. MutL-alpha is a 
heterodimer of MLH1 and PMS2, MutL-beta is a heterodimer of MLH1 and PMS1, whereas 
MutL-gamma is a MLH1/MLH3 heterodimer. 
 
For a defective MMR system to exist both alleles of any one of the MMR genes must be 
inactivated. Even though on a clinical level the syndrome is autosomal dominant, on a 
molecular level, germline mutations are recessive as evidenced by two hits being necessary to 
disable the gene. Generally, one allele of a MMR gene has a germline mutation and the 
second gene is inactivated somatically by mutation, loss of heterozygosity or epigenetic 
silencing by protein hypermethylation. Once both alleles are inactive, mutation rate increases 
leading to genomic instability due to the failure of the MMR system to repair the DNA 
mismatches. DNA mismatches generally occur in areas of repetitive nucleotide sequences 
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known as microsatellites. Expansion or contraction of these microsatellite regions is known 
as microsatellite instability (MSI) and is characteristic of what happens when there is loss of 
mismatch repair in Lynch-associated cancers. Failure of mismatch repair affects not only the 
DNA MMR genes but also genes that control cell growth and apoptotic processes. 
Accumulation of mutations in these genes is thought to be the driving force behind 
carcinogenesis [36,37]. Finally, deletions in the 3’ terminal codon of the EPCAM gene, leads 
to inactivation of the MSH2 gene found neighbouring the EPCAM gene. Mosaic inactivation 
of the MSH2 gene in cells that express EPCAM 3’ end deletion results in tumours that are 
different from typical germline MSH2 mutations or deletions but phenotypically are similar 
to LS [38]. 
 
1.3.2 Clinical features. 
 
Colonic manifestations: Most individuals with LS are asymptomatic until they present with 
features of CRC. The lifetime (70 year) risk of CRC in patients with LS ranges from 10% to 
47% and to a degree is influenced by the sex of the patient and the mutated MMR gene 
(Table 1) [39-44]. In general, CRC resulting from LS presents at a younger age than sporadic 









Table 1. Lifetime cancer risk related to Lynch genotypes [39-44] 
MLH1  MSH2  MSH6  PMS2  
Men Women Men Women Men Women Men Women 
Any Lynch cancer 59% 80% 71% 75% 31% 71% - - 
34 to 36 to 37 to 33 to 14 to 10 to 19 to 11 to 





21 to  
NA 
16 to  
NA 
12 to 
54% 51% 49% 24% 
 
Ovarian NA 












  20%     
Urinary tract 1.2% 3% 8% 10% 0.7% - 
Gastric 20% 8% 2% 9% - - 
Small bowel 0.4%*  1.1%*  - - 
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Biliary/pancreatic 1.9%* 0.02%* - - 
Brain tumours 
(gliomas) 
1.7%* 2.5%* - - 
 
 
NA: not applicable. * Not reported separately by sex. 
 
 
Synchronous (at the same time) and metachronous (at another time) tumours occur more 
frequently in patients with LS and approximately 7% of patients have more than one tumour 
at the time of their presentation [45]. It has been shown that development of a metachronous 
CRC in a patient who underwent segmental resection of their 1st cancer occurred in 16% at 10 
years, 41% at 20 years and 62% at 30 years. In those patients where the primary tumour was 
rectal, 14% developed metachronous tumours at 10 years, 47% at 20 years and 69% at 30 
years [46,47]. 
 
Lynch related CRC shows a predilection for the right side of the colon. These tumours tend to 
develop from larger, flatter, more proximal adenomas/polyps and exhibit higher rates of high- 
grade dysplasia and/or villous histology than sporadic adenomas/polyps. The adenoma- 
carcinoma sequence is also greatly accelerated in LS versus sporadic CRC (35 months versus 
10-15 years). The overall 10-year survival for Lynch related CRC is high at approximately 
91% [48]. 
 
Extracolonic manifestations: LS is associated with the development of extracolonic tumours 
of which endometrial cancer is the commonest. Risk depends on the MMR gene mutated and 
is illustrated above (Table 1) [39-44]. Other common cancers include cancers of the ovary, 
stomach, small bowel, hepatobiliary system, renal pelvis and ureter, brain (glioma, Turcot 
syndrome), sebaceous neoplasms (Muir-Torre syndrome). Cancer of the pancreas, prostate, 
breast and cervix have also been reported but are rare [42,49-57]. 
 
Genotype phenotype correlation: With regards to the four MMR genes, PMS2 mutations 
have the lowest penetration (Table 1). Due to the inherent cancer risk associated with any of 
these mutated genes, the screening and treatment of at-risk individuals is not modified to the 
gene involved and remains the same regardless of the gene mutated. The risk of CRC and 
endometrial cancer is approximately the same in MLH1 and MSH2 mutations, however the 
overall cancer risk is greater for those with a MSH2 gene mutation, especially where 
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urothelial cancers and sebaceous tumours are concerned (Table 1) [40,42,58]. With regards to 
EPCAM mutations, risk of progression to cancer is similar to those with MSH2 mutations. 
The risk of endometrial cancer is lower when compared to those with MSH2 mutations unless 
the base pair deletion extends close to the promoter region of MSH2[59,60]. MLH1/MSH2 
mutations have higher penetrance when compared to MSH6/PMS2. MSH6/PMS2 mutations 
exhibit an attenuated cancer phenotype and a later age at which cancer is first diagnosed [38- 
40]. 
 
Histological features of Lynch-associated CRC include mucinous, signet ring or medullary 
histologic type. They are poorly differentiated and have a brisk lymphocytic infiltrate or are 
rimmed by a Crohn-like, germinal centre-producing lymphoid reaction [61,62]. 
 
1.3.3 Identification of individuals at risk for Lynch Syndrome. 
LS is largely under-recognized [63]. Historically the primary tool to identify individuals was 
family history of CRC and other cancers. These family history-based strategies have been 
shown to have poor sensitivity and specificity for identifying patients with LS. After 
recognising that Lynch-associated CRCs exhibit MSI, tumour testing has become an 
important adjunct in identification of individuals with LS and their families. 
 
Clinical criteria: The Amsterdam I criteria were proposed in 1990 to help identify families 
likely to be mutation carriers for LS. However, the Amsterdam I criteria was found to be too 
rigid and in 1998 was expanded to include the extracolonic cancers associated with LS. This 
expansion resulted in the present-day Amsterdam II criteria with a sensitivity and specificity 
of 22% and 98% respectively [64,65]. 
 
For the Amsterdam II criteria to be fulfilled each of the following must be met: 
 
• 3 or more relatives with an associated cancer (CRC, or cancer of the 
endometrium, small intestine, ureter or renal pelvis). 
• 2 or more successive generations affected. 
• 1 or more relatives diagnosed before the age of 50 years. 
• 1 should be a first-degree relative of the other two. 
• FAP should be excluded in cases of colorectal carcinoma. 
• Tumours should be verified by pathologic examination [66]. 
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In 1997 (with a revision in 2004) a new set of recommendations called the Bethesda 
guidelines were published by the National Cancer Institute for the purpose of identifying 
individuals who should undergo genetic testing for LS related tumours. 
 
The revised Bethesda Guidelines are as follows [65,67,68]: 
 
• CRC diagnosed in a patient who is less than 50 years old. 
• Presence of synchronous or metachronous CRC or other LS-associated tumours, 
regardless of age. 
• CRC with MSI-H histology diagnosed in a patient less than 60 years old. 
• CRC diagnosed in one or more first-degree relatives with a LS-associated tumour, 
with one of the cancers being diagnosed at less than 50 years of age. 
• CRC diagnosed in two or more first-degree or second-degree relatives with LS- 
associated tumours, regardless of age. 
 
The revised guidelines have been found to be more sensitive (82%) and specific (77%) than 
the Amsterdam II criteria in identifying individuals and families at risk of developing LS 
[67]. 
 
Prediction models: Several computational clinical prediction models have been developed as 
an adjunct to clinical criteria and clinical suspicion to better estimate the risk of a MMR gene 
mutation and identify individuals and families who would benefit from genetic testing. Three 
well known risk prediction models are the MMRpredict, MMRpro and PREMM models [69- 
72]. The MMRpredict model has been validated in a study involving 725 consecutive patients 
with CRC whose MMR status was available, the sensitivity and specificity of the model is 
94% and 91%, respectively [73]. The MMRpro model estimates the chance of germline 
mutations in MLH1, MSH2, MSH6 genes. MMRpro also serves to estimate future risk in 
unaffected individuals or mutation carriers and untested persons. The MMRpro model, in 
validation studies has been shown to be more discerning than the Bethesda criteria [74]. Of 
the three models, the PREMM has the highest sensitivity but lowest specificity (90% and 
67%, respectively) [63] and when followed by genetic testing seems to be cost effective in 
individuals between ages of 25-35 years in whom the risk estimate exceeds 5% [75]. 
 
Tumour-based strategies: Some experts advocate universal testing of all CRCs while others 
employ a selective strategy of tumour testing reserved for high risk individuals [63,76-80]. 
Evidence suggests that universal testing has a slightly greater sensitivity for identifying 
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individuals with LS when compared to other strategies, including the Bethesda criteria, or 
other selective tumour testing strategy. However, the diagnostic yield from universal testing 
and selective testing is comparable and in fact selective approaches resulted in far fewer cases 
needing tumour testing and germline testing without a significant decrease in diagnostic yield 
or strain on resources [31,81,82]. 
 
MSI testing: Due to loss of DNA MMR genes, tumours in LS demonstrate MSI. MSI testing 
is done using polymerase chain reaction (PCR) to amplify DNA sequences containing 
nucleotide repeats. If more than 30% of the markers in a panel show expansion or contraction 
of these sequences in a tumour when compared with normal mucosa from the same patient, 
the tumour is said to be MSI-H. the sensitivity and specificity of MSI testing are 85% and 
90% respectively [61]. However, MSH6 associated cancers can sometimes be missed on MSI 
testing as MSH6 mononucleotide markers are not included in all MSI panels [59]. 
 
Immunohistochemistry: Immunohistochemistry (IHC) can be used to detect loss of staining 
of MMR protein that occurs in LS with a sensitivity and specificity of 83% and 89% 
respectively. It is inexpensive, easily accessible and can be performed on small biopsies with 
the added benefit of being able to determine the exact gene which may be the problem 
[83,84]. In addition, IHC can also be used on endometrial tumour samples to detect LS, 
though the evidence is lacking with regards to other Lynch associated tumours and abnormal 
IHC results in these should be evaluated along with family and personal history before 
diagnosing Lynch syndrome. IHC (and MSI) can also be used in testing of large (>1cm) 
adenomas/polyps if no CRCs are available for testing in a family, but it must be kept in mind 
that the absence of MSI in these cases does not rule out LS and further testing is needed if 
enough suspicion exists [85,86]. 
 
1.3.4 Diagnosis of Lynch Syndrome. 
LS should be suspected in individuals who exhibit the following: 
 
• synchronous or metachronous CRC. 
• CRC prior to 50 years of age. 
• multiple LS associated cancers. 
• familial clustering of LS associated cancers. 
 
Before a definitive diagnosis is made a pathogenic germline mutation in the MMR gene or 
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EPCAM gene is required. Sequential genetic evaluation of patients suspected to have LS 
begins with tumour testing. Germline testing on all patients is not viable due to the exorbitant 
expense [57,87]. 
 
Genetic evaluation should be considered in the following individuals: 
 
• All newly diagnosed patients with CRC (alternatively, those diagnosed prior to age 70 
years). 
• Endometrial cancer prior to age 60 years. 
• First-degree relative of those with known MMR/EPCAM gene mutation. 
• Individuals with a CRC with a >5 % chance of a MMR gene mutation by prediction 
models. 
• Family cancer history meeting Amsterdam I or II criteria or revised Bethesda 
guidelines. 
 
Tumour evaluation: Genetic evaluation begins with MSI and/or IHC testing. If no MSI is 
found and all four MMR proteins are intact on IHC, this effectively rules out most cases of 
LS. If evidence of MSI-H or loss of expression of a MMR protein is noted further evaluation 
is based on the MSI/IHC results and outlined in the algorithm below. 
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Figure 3. Tumour evaluation algorithm [88]. 
MSI: microsatellite instability; IHC: immunohistochemistry; MSI-L: low MSI; MSS: 
microsatellite stable; MSI-H: high MSI; MMR: mismatch repair [88]. 
 
Germline testing: Germline testing is required to establish the definitive diagnosis of LS. 
Comprehensive germline mutation testing involves gene sequencing and deletion/duplication 
analyses Germline testing should be offered to the following individuals: 
 
• Patients with microsatellite unstable tumours by MSI/IHC testing. 
• If tumour testing is not feasible and if the clinical suspicion of LS is strong (e.g., 
individual meets revised Bethesda criteria). 
• If a patient meets the Amsterdam criteria, some experts recommend germline testing 
without prior tumour testing. 
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Once a pathogenic MMR/EPCAM mutation is found the diagnosis of LS is established. At- 
risk relatives should then be referred for genetic counselling and site-specific testing for the 
mutation to determine the pedigree. Screening should be started in at risk individuals from 
the ages of 20 to 25 years or at 10 years before the earliest onset of cancer in the family. 
 




LS: Lynch syndrome; CRC: colorectal cancer. 
 
1.3.5 Cancer screening and surveillance of Lynch Syndrome. 
Guidelines for cancer screening for individuals with LS are largely based on expert opinion 
and limited observational data [89,90]. The United States Multi-Society Task Force on 
Colorectal Cancer and the American College of Gastroenterology recommend the guidelines 
discussed below. 
 
All patients with a definitive diagnosis of LS should undergo screening for associated 
cancers. Individuals at risk for LS with indeterminate genetic results and those who have not 
undergone genetic evaluation should also be considered for screening depending on their 
personal and family history and evidence of MSI on tumour testing. 
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Colorectal cancer: Colonoscopic surveillance in individuals with LS should begin at age 20 
to 25 years (at one or two-year intervals), or two to five years before the earliest age of CRC 
diagnosis in the family. The exception to this is families with MSH6 and PMS2 mutations 
which are known to have a lower CRC risk and a later age at CRC diagnosis. Colonoscopic 
screening in these individuals with an attenuated phenotype can begin at age 25 to 30 or two 
to five years prior to the earliest CRC in the family, repeated every one to two years [57,87]. 
Colonoscopy has been shown to significantly decrease cancer related mortality in individuals 
with LS. Additionally, colonoscopic surveillance of at-risk family members have been 
associated with a gain of 14 quality-adjusted life years per screened individual versus no 
screening [95]. A fifteen-year prospective study published in 2000 studied 22 families with 
LS and compared cancer incidence and mortality between 133 regularly screened at-risk 
members and 119 members who had refused screening. Participants who underwent 
colonoscopic screening at approximately 3-year intervals had a lower CRC incidence (6% 
versus 16%) and overall mortality (8% versus 22%) as compared with the unscreened group 
[93]. With regards to interval timing of surveillance colonoscopy, there have been no 
randomized trials done to determine the optimal interval between colonoscopes. 
Observational studies, and prospective cohort studies, however, have found that annual 
colonoscopy currently is appropriate [92,94,96,97]. 
 
Endometrial and ovarian cancer: Women with LS, starting at 30 to 35 years of age or three 
to five years before the earliest age of diagnosis of these cancers in the family should undergo 
annual pelvic examination with endometrial biopsies taken to look for endometrial cancer as 
well as have transvaginal ultrasound done to detect ovarian cancer [57,87]. Prophylactic 
hysterectomy and bilateral salpingo-oophorectomy at the end of childbearing or around age 
40 years for mutation carriers is also recommended. Those who do not consent to surgery 
need to continue screening annually. 
 
Other Cancers: Screening for gastric cancer in LS is controversial and not recommended 
[91]. Lifetime risk of small bowel cancer in LS is small (0.4% to 12%) and routine screening 
currently is not recommended as it is not cost effective [63,98]. However, the National 
Comprehensive Cancer Network (NCCN) guidelines controversially do suggest that wireless 
capsule endoscopy be considered at two- to three-year intervals. Regarding urinary tract 
cancers, the recommendations are for annual urine analysis starting from age 30-35 years 
[57,87,91,99]. Annual skin examinations to detect sebaceous tumours and cutaneous 
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keratoacanthomas associated with Muir-Torre syndrome are recommended [100]. As per 
current guidelines screening for pancreatic cancers should be reserved for individuals with a 
MMR mutation and a first degree relative with pancreatic cancer. Routine screening is not 
recommended [87,101]. 
 
1.3.6 Management of Cancer. 
The ideal surgical management of an individual with LS who is found to have CRC or 
endoscopically unresectable adenoma is total abdominal colectomy with ileorectal 
anastomosis followed by annual endoscopic surveillance of the remaining rectum. Segmental 
colectomy with annual postoperative surveillance should be reserved for patients who are not 
candidates for total colectomy [87]. Individuals who undergo segmental colectomy are at 
greater risk of a subsequent adenoma/polyp or carcinoma as compared to those who have had 
a total colectomy [47,102]. Women should be offered prophylactic hysterectomy and bilateral 
salpingo-oophorectomy at the time of colectomy. The role of chemotherapy in Lynch 
associated CRC is currently controversial. Most are MSI-H and are often poorly 
differentiated. The effect of chemotherapy on these cancers is currently unknown. 
Fluorouracil seems to have little effect on MSI-H tumours whereas in some studies irinotecan 
seemed to have increased efficacy against MSI-H tumours. Ultimately more studies need to 
be conducted before recommendations can be given [103]. 
 
1.4 Lynch syndrome in South Africa 
Historic LS data in South Africa is unfortunately lacking. The index case of LS in South 
Africa dates back to 1985 when LS was first described in South Africa. The index case 
involved a 30-year-old male who developed CRC with a family pedigree spanning over four 
generations. Most of the available data in South Africa pertaining to LS comes from around 
50 satellite families consisting of approximately 2000 individuals located in the Northern 
Cape Province of South Africa. This cohort of individuals has been identified over the years 
through genetic testing of at-risk family members104. 
 
1.4.1 Colorectal cancer screening and surveillance in South Africa. 
At the time of writing no formal CRC screening or surveillance program exists in South 
Africa. The South African experience with regards to LS is enhanced by the Annual Northern 
Cape Colonoscopy Outreach program. This mobile service provides annual genetic testing 
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and surveillance colonoscopy in small district hospitals and clinics in the Northern Cape and 
makes quality surveillance accessible to an at-risk group who may otherwise find annual 
screening an economic and logistical challenge. At risk individual and their family members 
upon reaching the age of 18 years undergo genetic counselling and site-specific testing to 
determine if a MMR mutation is present. Patients identified as having an MMR gene 
mutation undergo surveillance colonoscopy every 2 years starting at age 18 years, then 
annually from 30 years old [105]. In line with international evidence, mobile surveillance 
colonoscopy has been shown to have improved outcomes overall, and in CRC-related 
survival rates in individuals carrying a single MMR gene mutation [106]. One of the main 
challenges the mobile surveillance program faces is that with each year compliance with 
surveillance colonoscopy is decreasing with a 2007 study showing fewer than 25% adhering 
to all their recommended screening appointments [107]. Major factors identified for 
noncompliance were financial constraints (18%), logistical difficulties (16.4%), the 
unpleasant experience of bowel preparation (16.4%) and pain (4.9%) as a reason for 
nonattendance. 
 
1.4.2 Role of EndoRings™ in surveillance colonoscopy for Lynch Syndrome. 
Colonoscopy is currently the gold standard for detection and removal of colorectal 
adenomas/polyps that if left unchecked develop into CRC [108,110]. Despite being the best 
available and most sensitive method for adenoma/polyp detection, colonoscopy is not without 
its limitations. The most serious limitation being that precancerous lesions can easily be 
missed during standard colonoscopy due to patient factors, examiner factors, poor bowel 
preparation, flat lesions and hidden lesions (in haustral folds and colonic flexures) (Table 2) 
[109,110]. Older studies place adenoma/polyp miss rates by standard colonoscopy to be 
approximately 20-25%. With newer studies, while evaluating technologies that improve 
colonic visualisation, miss rates using standard colonoscopy approach 40%. This has serious 
implications regarding morbidity and mortality of at-risk individuals. Standard colonoscopes 









  Table 2. Factors influencing the adenoma detection rate (ADR) [109]. 
 
 
In an attempt to increase ADR/PDR multiple new technologies have been developed to 
improve colonic visualisation in the hopes of positively influencing the above while 
maintaining the capabilities that standard colonoscopy offers. These technologies range from 
less practical and more expensive inventions such as Full Spectrum Endoscopy (FUSE), 
Third eye technologies, virtual chemo-endoscopy to more practical and relatively more 
affordable devices such as EndoCuff™, cap assisted colonoscopy and the subject of this 
study - the EndoRings™ [108-110]. 
 
The EndoRings™ is a silicone-rubber device that fits onto the distal end of a colonoscope. It 
boasts flexible circular ‘petals’ (rings) that allow easy intubation to the caecum but upon 
withdrawal stretches out the haustral folds of the colon to allow for better visualisation of the 
mucosal surface. Additionally, the rings provide a stabilising anchor that prevents slippage 
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of the scope and keeps it centred in the lumen when preforming interventions such as snaring 
or taking biopsies [108-110]. 
 
There is a lack of abundant data available with regards to the actual benefit that these devices 
provide but from the evidence we have it is generally suggested that techniques like FUSE, 
Third Eye and retroflection colonoscopy are promising but involve a significant financial 
investment to be feasible [108,109]. Staining techniques and water infusion technologies 
might be useful in select patients but are too time consuming to be used for screening 
purposes [109]. Cap assisted colonoscopy results are equivocal with some studies showing 
improvement and some showing no difference in ADR/PDR. EndoCuff™ assisted 
colonoscopy again is promising but not all randomised trials show superiority of EndoCuff™ 
to standard colonoscopy [109]. With regards to EndoRings™ only one major randomized 
control trial has been completed, the CLEVER trial, which reported a statistically significant 
reduction in missed adenomas with EndoRings™ (14%) versus standard colonoscopy (48%). 
However, it should be noted that the CLEVER trial was funded by EndoAid Limited, the 
company that produces the EndoRings™ device [108-110]. It is clear that more studies are 
needed evaluating the absolute efficacy of these novel devices before major changes to 
current practice can be implemented, especially in the South African setting. Ultimately the 
major factors that influence improved ADR/PDR and are more cost effective to enact are the 
expertise of the endoscopist, optimal bowel-cleansing, correct withdrawal times, meeting 
quality markers for screening colonoscopy as set by ASGE and patient compliance with 
screening intervals [109].
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Chapter 2: Publication ready manuscript. 
2.1 Introduction. 
Lynch syndrome (LS) is an autosomal dominant disorder characterised by specific germline 
mutations in one of the four DNA mismatch repair (MMR) genes (MLH1, MSH2, MSH6, 
PMS2) or the EPCAM gene [1]. Historically known as hereditary non-polyposis colorectal 
cancer (HNPCC) (which is defined clinically, usually by satisfaction of the Amsterdam I or II 
criteria, in the absence of a known genetic mutation) it is the most common of the inherited 
syndromes that significantly increase the life time risk of developing colorectal cancer (CRC) 
as well as cancers of multiple other organs (endometrium, stomach, ovaries etc.) from 5% in 
the general population to 18%-53% depending on the gene affected [2]. Progression to CRC 
in these individuals is accelerated (1-2 years) and cancers tend to develop at a younger age 
when compared to non-hereditary CRC. Additionally, individuals who do go on to develop 
CRC are at significant risk of synchronous tumours or of developing metachronous tumours 
after their index surgery, depending on the type of surgery performed (15% at 10 years, 40% 
at 20 years, 60% at 30 years) [3]. Even though the name HNPCC may suggest an absence of 
adenomas/polyps, individuals with LS can certainly develop a few adenomas/polyps. These 
are usually fast growing, flat and more prevalent in the right colon displaying higher grades 
of dysplasia and villous histology [4]. 
 
Estimates suggest that 1 in 300 individuals carry mutations in their DNA MMR genes. 
Though not all carriers progress to cancer, LS still accounts for approximately 3%-5% of all 
newly diagnosed CRCs yearly. Currently LS is still under recognised. Multiple clinical 
criteria (Amsterdam I & II, Bethesda), prediction models (MMRpredict, MMRpro) as well as 
tumour-based strategies have been developed as adjuncts to clinical suspicion to better 
identify individual and families who would benefit genetic testing [5-10]. Current 
international consensus guidelines recommend that high-risk individuals with LS undergo 
screening colonoscopy every 1-2 years beginning at 20-25 years of age or 2-5 years prior to 
earliest age of CRC in the family (whichever occurs 1st), repeated ever 1-2 years. Several 
screening recommendations for extracolonic Lynch associated cancers also exist [11-14]. 
 
CRC in South Africa is the 4th most common cancer among both men and women. Crude 
incidence rate is 6.5-8.5/100000 yearly [15]. The Northern Cape is the largest and most 
sparsely populated province in South Africa with a predominantly Afrikaans speaking 
population. In the Northern Cape CRC incidence is relatively lower at 3-4/100000, however 
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it has been shown that 10.5% of these cancers have a MMR gene mutation, translating to 
three times the normal international rate in high incidence areas [16,17]. The majority of the 
LS data from South Africa comes from 50 satellite families (2000 individuals) from the 
Northern Cape. 
 
At the time of writing no national CRC/LS screening and surveillance program exists in 
South Africa. However, the South African experience with regards to LS is enhanced by the 
Annual Northern Cape Colonoscopy Outreach Program. In the remote areas of Northern 
Cape, the Colorectal Unit of the University of Cape Town and Groote Schuur Hospital has 
provided an annual (August/September) outreach colonoscopy service for mutation positive 
individuals for the past 21 years. Each annual trip spans a period of one week (preceded by a 
preparatory and informative trip) and involves visits to 4-5 district towns by specialists, 
nurses, registrars, technicians from the GSH colorectal department and over the past few 
years gynaecological and breast services as well [16,18,19]. It has been shown that 
individuals who comply with the outreach service benefit from overall and CRC related 
survival extending their lifespan by up to 20 quality adjusted life years [19]. Outreach 
colonoscopy has been shown to provide a safe, cost-effective and comparable service to 
impatient colonoscopy in this setting [20]. However, the outreach service does face several 
challenges. These include challenges with patient adherence to the service (25% obtained 
100% adherence) and poor compliance with bowl preparation prior to colonoscopy, resulting 
in a steady decline in attendance over the years [1]. Major factors influencing this decline are 
mostly economical and logistical in nature. Pain and discomfort are other major deterrent 
factors. Any traumatic experiences likely result in further non-compliance of not only the 
individuals involved but also other family members. Therefore, it is essential to have experts 
providing the service to make the experience as smooth as possible for the patients. Having 
experts also limits the number of major complications (e.g. perforation) which is of 
paramount importance as the nearest metropolitan hospital is usually hours away from the 
towns where the service visits. 
 
Colonoscopy as we know is a colon inspection and intervention technique involving a fibre 
optic instrument being inserted through the anus for colonic visualisation and/or intervention. 
Standard colonoscopy is currently the gold standard for detection and removal of colorectal 
adenomas and polyps, the precursor lesions of most CRCs [19,21]. Despite being the most 
sensitive surveillance method for prevention of future CRCs, colonoscopy is not without its 
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limitations, particularly in terms of visualisation of the entire colon [22]. Known causes of 
missed precancerous lesions include inadequate bowel preparation, difficulties in detection of 
flat, small (1mm -5mm) lesions and lesions on the proximal side of haustral folds and the 
internal curves of colonic flexures [23,24]. Several studies have reported the adenoma/polyp 
miss rates of standard colonoscopy to be approximately 20–25%, with newer studies citing 
miss rates approaching 40% [25,26]. This has created a need for the development of novel 
technologies/techniques to improve visualisation of the colon especially behind colonic folds 
and flexures. 
 
Several technologies such as cap-assisted colonoscopy, virtual chromo endoscopy, Third Eye 
colonoscopy, Full Spectrum Endoscopy (FUSE) colonoscopy, EndoCuff™ and EndoRings™  
(Fig 4.) exist to try improving adenoma detection rate (ADR)/polyp detection rate (PDR), 
however their true efficacy remains to be established conclusively [24,27]. Arguably some 
positive evidence for the use of cuff devices such as EndoCuff™ (2 RCTs) and EndoRings™ 
(1 RCT) with regards to increased ADR/PDR in at risk individuals exists, however too few 
studies currently exist to draw any definitive conclusions as to their benefit. EndoRings™ is a 
silicone-rubber device that is fitted onto the distal end of the colonoscope. The alleged 
improvement in detection of adenomas/polyps offered by the EndoRings™ is provided by 
three circular rows of flexible silicone rubber rings that engage and mechanically straighten 
the colonic folds during withdrawal (Fig 4.) [1]. The EndoRings™ additionally improves 
visualization of the total colonic surface area by keeping the distal tip of the colonoscope 
centred in the colonic lumen and stabilizing the scope tip where interventions are needed. 
Colonoscopy with the EndoRings™ does not interfere with the normal washing, suctioning, 
and therapeutic capabilities of the colonoscope and does not block parts of the camera view 
as is the case with some of the other devices [1]. 
 
The utility of EndoRings™ in terms of increased ADR/PDR has not been studied in the 
South African setting. The primary objective of this study therefore aims to determine the 
efficacy of EndoRings™ assisted colonoscopy in terms of ADR/PDR when compared with 
standard colonoscopy in individuals with Lynch syndrome. The primary endpoint of this 
study measures the number of adenomas/polyps detected within both study arms and 
provides a comparison of the two. Secondary end points include intubation time, 
withdrawal time, total procedure time, complications and adequacy of bowel preparation in 
both arms.  
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2.2 Methodology. 
The study was designed as a cross sectional randomized controlled trial after obtaining 
ethical approval from the Research Ethics Committee of the University of Cape Town 
(HREC number 536/2015). A total of 57 individuals from the Northern Cape province of 
South Africa with LS awaiting scheduled surveillance colonoscopies were enrolled into the 
study over a one-week period during the Annual Northern Cape Colonoscopy Outreach trip 
for the year 2015. Individuals satisfying the inclusion criteria (n = 54) were enrolled and 
informed consent (in local language of preference) was obtained from each individual for the 
colonoscopic procedure as well as for the study (see appendix for consent form). Those not 
meeting the inclusion criteria and those who refused to provide consent were excluded (n = 
3). All study participants were well informed about the study details, the risks, benefits and 
alternatives and had an extended opportunity to ask any questions. Identity of participants 
was kept anonymous throughout and all data was recorded on numbered data sheets without 
any personal identifiers (see appendix). Study participants were randomised blindly using 
computer randomisation to a control arm undergoing standard colonoscopy and a study arm 
undergoing EndoRings™ assisted colonoscopy, each arm numbering 27 participants. 
 
All colonoscopies were performed by experienced senior colorectal and gastrointestinal 
consultants to maintain standards. Bowel preparation was started 24 hours prior to the 
procedure using MOVIPREP™ according to the standard bowel preparation protocol 
provided by the manufacturer. A stopwatch was used to measure caecum intubation time. A 
photograph of the appendix orifice was used to confirm complete colonoscopy. The time 
stamp on the photograph was used as the reference for the start of the withdrawal time. At the 
end of the procedure, a photograph of the distal rectum and anus was taken with a retroflexed 
colonoscope. The time stamp on this photograph served as the end of procedure time. Time 
spent removing polyps and cleaning the colon was documented and subtracted from the total 
withdrawal time (caecum to rectum) to determine net withdrawal time. Pethidine and 
Midazolam were administered for analgesia and sedation. All relevant data, including patient 
demographics, primary outcome (number of adenomas/polyps detected) and secondary 
outcomes (procedure times and bowel preparation and complications) were recorded on data 
sheets during the procedure in real-time by a registered nurse or surgical trainee so as not to 








• Known LS MMR gene mutation carriers undergoing scheduled surveillance 
colonoscopy during the Annual Northern Cape Colonoscopy Outreach trip. 




• Individuals under the age of 18 years. 
• Individuals with a history of inflammatory bowel disease, known colonic stricture and 
history of other polyposis syndromes (FAP, MAP). 
• Refusal to provide informed consent. 
 
Statistical analysis. 
A power calculation (R, 64 bit, version 3.1.3) was carried out using a z-test to compare the 
means of the number of polyps expected in the two arms (with a significance level of 5% and 
assuming that the variances were known).  The distribution for the mean number of polyps 
was normal, using large sample theory (central limit theorem).  However, the results should 
be treated with caution especially at the smaller sample sizes.  To calculate the sample size 
required for a study power of 80%, six hypothetical contexts were considered (see Appendix 
E for all six scenarios).  Using hypothetical context 5 (Fig 5. below) for our best estimates 
(based on current studies), it was determined that a total of 80 individuals (40 in each arm) 
were needed to have an 80% chance of detecting a significant difference in the means 
between the two arms at a 5% significance level, based on a coefficient of variation of 
100%,and assuming a true mean of 0.2 polys in Arm 1 (10 polyps/50 colons), and a mean of 
0.4 in Arm 2 (20 polyps/50 colons). The distribution of the number of polyps per colon was 
heavily right-skewed, as a large proportion of 0 polyps were expected. 
 
Data analysis was performed using an IPython kernel in a Jupyter notebook together with the 
numerical python, scientific python, statsmodels, and scikit.bootstrap libraries. Data 
management was performed using the pandas library and plotting was based on the 
matplotlib library. Descriptive statistics used mean and median as point estimates and 
standard deviation, range, and 95% confidence intervals as measure of dispersion. The 
assumptions for the use of parametric tests were done using the Shapiro-Wilk test and 
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examination for statistical outliers. Student’s t-test and analysis of variance we used to 
compare numerical variables if these assumptions were met. The Mann-Whitney-Wilcoxon 
and Kruskal-Wallis tests were used as non-parametric alternatives. Univariate linear 
regression was used to compare numerical variables. Proportions we compared using the χ 2 
for independence. A confidence levels of 95% was used throughout. Unless otherwise 
indicated, a two-tail test hypothesis was used with an alpha-value of 0.05 as discriminator for 




  Demographics. 
Out of a total of 57, data for 54 colonoscopies was available for analysis. Three individuals 
were excluded for protocol violations. All enrolled individuals agreed to participate in the 
study. The use of EndoRings™ during colonoscopy was randomly assigned by computer 
randomisation, with 27 individuals in each study arm. Colonoscopies were performed on 34 
(63%) females and 20 (37%) males. The male cohort was slightly older, with a mean age and 
standard deviation (SD) of 46.3±18.1 (range: 22 to 82) years versus a mean age and SD of 
42.4±12.7 (range: 20 to 64) years for the female cohort (P = 0.55) as shown in Fig 1. below. 
 
The mean age of all participants who underwent EndoRings™ assisted colonoscopy was 
43.98±15.27 years (range: 20 to 57, 95% CI 33.9 to 42.8 years) compared to a mean age of 
44.26±14.67 years (range 22 to 82, 95% CI 43.6 to 55.2 years) for those who underwent 
standard colonoscopy (P = 0.05).The female to male ratio in the EndoRings™ group was 
19:8 versus 15:12 in the standard colonoscopy group (P = 0.40). 
 
In both arms, out of 27 patients, 24 patients (88.9%) had previously had a colonoscopy and 
25 patients (92.6%) successfully completed their colonoscopy. Out of the 27 patients, 10 
patients (37.04%) in the standard colonoscopy arm and 4 patients (14.8%) in the 
EndoRings™ arm had had prior surgery (segmental resections (11) and subtotal colectomy 
(3) with ileorectal anastomosis. 4 colonoscopies (2 in each arm) could not be carried out to 
completion due to colonic narrowing. 
 
Bowel preparation and procedure time. 
Using the Harefield Cleansing Scale, bowel preparation during colonoscopy was reported as 
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excellent in 48.1% (n = 13) of cases in both arms, good in 33.3% (n = 9) and 44.4% (n= 12), 
and fair in 18.5% (n = 5) and 7.4% (n = 2) of cases in the standard colonoscopy versus 
EndoRings™ arms respectively. The variations in the adequacy of bowel preparation in both 
arms did not influence the completion of the procedures (P = 0.49) or the number of polyps 
detected (P= 0.24). We found the total time taken to complete the colonoscopy was 
somewhat influenced by the adequacy of the bowel preparation. Excellent preparation - mean 
time to completion 22.4 minutes (95% CI, 19.5 to 26.8 minutes), good preparation - mean 
time 31.2 minutes (95% CI, 25.1 to 38 minutes) and fair preparation - mean time 24.1 
minutes (95% CI, 21 to 26.4 minutes) as shown in Fig 2, though this was not clinically or 
statistically significant. 
 
As illustrated in Table 1, no significant differences were found with regards to time taken to 
reach the caecum (95% CI 12.3 to 18.9 minutes in EndoRings™ arm versus 95% CI 11.5 to 
17.9 minutes standard colonoscopy arm, P =0.84), the withdrawal time (95% CI 8.0 to 11.2 
minutes in EndoRings™ arm versus 95% CI 8.4 to 12.6 minutes in standard colonoscopy 
arm) (P = 0.84) as well as the total procedure time in both arms. Please refer to Appendix A 
for supplementary data. 
 
Adenoma/Polyp detection rate. 
Table 2 highlights the number of adenomas/polyps per person found as a percentage in both 
arms. The average number of adenomas/polyps detected in the EndoRings™ assisted 
colonoscopy arm was 1.4 versus 0.9 in the standard colonoscopy group (p = 0.60) as shown 
in Fig 3. Similarly, Table 3 displays the location of adenomas/polyps found in the different 
regions of the colon as well as the number of times adenomas/polyps were found in those 
areas. Furthermore, in both arms the size of adenomas/polyps detected were less than 1 cm in 
size and no large adenomas/polyps were reported in any individual. No complication 
occurred in the EndoRings™ assisted colonoscopy arm. Two individuals reported limited 
rectal bleeding immediately after their colonoscopy in the standard colonoscopy group (P = 
0.54). There were no device related issues such as dislodgement or impaction noted with the 
use of the EndoRings™ device, and no difference in the discomfort experienced during the 
procedures by the participants between the two arms. 
 
Subgroup analysis (exclusion of individuals with previous colon resections). 
Excluding individuals who had undergone previous colon resection yielded 23 individuals 
(n=27-4) in the EndoRings™ assisted colonoscopy arm (6 males/17 females) and 17 
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individuals (n=27-10) in the standard colonoscopy arm (8 males/9 females).  The total 
number of adenomas/polyps found in the former group was 20 (mean 0.86, SD 1.42) versus 
6 (mean 0.35, SD 0.76) in the standard colonoscopy group (see Table 4 below).  Analysis of 




Currently standard colonoscopy is the gold standard when it comes to detection and removal 
of premalignant lesions in the colon and rectum [1]. Despite being the best available 
technique, standard colonoscopy does have some serious limitations of which the most 
significant being the inability to adequately visualise the entirety of the colorectal mucosal 
lining [23]. Missed lesions hidden in the proximal aspects of haustral folds and flexures can 
have significant consequences in terms of morbidity and mortality for the individuals 
concerned [24]. In an attempt to improve visualisation of the colon and in effect increase 
detection rates of sinister lesions multiple novel techniques and devices have been proposed. 
The EndoRings™, a small silicone-rubber device which attaches to the distal end of the 
colonoscope is one such novel device and it has been proposed that EndoRings™ assisted 
colonoscopy increases total colonic visualisation, particularly in the folds and flexures as well 
as significantly reduces the adenoma/polyp miss rates associated with standard colonoscopy 
[23]. Therefore, the purpose of this randomised cross-sectional controlled trial was to 
investigate the efficacy in terms of increased ADR/PDR of the EndoRings™ device in the 
South African setting. In this study at risk individuals with LS presenting for their annual 
screening colonoscopy via the Northern Cape Outreach Colonoscopy program were divided 
into a control group undergoing standard colonoscopy and a test group undergoing 
EndoRings™ assisted colonoscopy. During the course of this particular study we were unable 
to demonstrate a statistically significant difference in ADR/PDR between the standard 
colonoscopy and EndoRings™ assisted colonoscopy groups (P = 0.60). The total number of 
lesions detected with standard colonoscopy were 24 (mean 0.9) as compared to 40 (mean 1.4) 
with EndoRings™ assisted colonoscopy.  Furthermore, subgroup analysis excluding all those 
individuals who had previously undergone colonic resection of any extent also failed to yield 
any statistically significant findings (P=0.34) between the two groups.  These findings are not 
in line with those reported by the CLEVER trial, the only other RCT comparing standard 
colonoscopy to EndoRings™ assisted colonoscopy to date. The CLEVER trial reported a 
significant increase in ADR/PDR during their study [23]. At the time of designing this study 
53  
we had anticipated a much larger cohort of LS affected individuals from the Northern Cape to 
present themselves for their annual screening colonoscopy than the number that actually 
attended their screening. This reduced sample size as well as constraints imposed on 
investigator time for the purpose of this study and logistical issues faced by the mobile 
surveillance team, contributed significantly to this study being under powered and may 
therefore be the reason why a statistically significant difference between the two arms could 
not be demonstrated (type 2 error). It should be noted that even though the CLEVER trial 
reported a significant difference in total detection rates in their trial, they too were unable to 
demonstrate a statistically significant difference in missed advanced adenoma/polyp rates 
(size > 10 mm, high grade dysplasia, villous architecture) [23]. 
 
In line with available data, we did not observe any statistically significant difference in the 
total procedure time, time to caecum and withdrawal time between the two arms. In an 
attempt to maintain uniformity time taken to carry out interventions (e.g. polypectomies) was 
not considered for analysis in either arm. Overall bowel preparation was found to be excellent 
in 26, good in 21 and fair in 7 individuals according to the Harefield Cleansing Scale and did 
not have any impact on ADR/PDR in this study. Completion of colonoscopy could not be 
achieved in 4 individuals (2 in each arm). All these individuals had previous 
abdominal/colonic surgery causing some degree of colonic narrowing limiting the 
progression of the scope. Two individuals reported experiencing complications post 
colonoscopy (minor bleeding), however these complications were found in the standard 
colonoscopy arm alone whereas no complications were reported in the EndoRings™ assisted 
colonoscopy arm. As expected, lesions were more frequently encountered in the proximal 
colon in both study arms (n = 9 standard colonoscopy, n = 13 EndoRings™ assisted 
colonoscopy) but once again out of line with the CLEVER trial there was no clinically 
significant difference between the two arms. According to the manufacturer, EndoRings™ 
improve total colonic visualisation by not only straightening out the colonic folds by also 
stabilises the scope tip within the lumen. The device does not interfere with washing, 
suctioning and the therapeutic capabilities of the scope and does not block any part of the 
camera view [28]. Anecdotal evidence from our endoscopists supports this claim as we found 
that the use of the EndoRings™ did in fact mechanically straightened the colonic folds and 
stabilise the scope within the colonic lumen without compromising vision or ability to 
perform interventions. Another advantage of the EndoRings™ device is that it readily fits 
most available colonoscopes and is therefore relatively inexpensive when compared to other 
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novel devices (e.g. FUSE). This may be of some consideration for cash strapped departments 
wishing to adopt the technology. 
 
As eluded to above our study had some limitation. In addition to the small sample size to 
achieve power, the study may have benefited from back to back comparison of ADR/PDR 
using standard colonoscopy followed by EndoRings™ assisted colonoscopy on each 
individual patient rather than splitting the patients into two arms each undergoing one 
colonoscopy. However, this would have been an impossibility for us as the mobile unit 
moves through five towns in the week that it operates, attempting to provide a desperately 
needed service to a dwindling and already apprehensive population. The time and resources 
required in subjecting an individual to two procedures one after the other in small district 
hospitals, many without proper surgical services should a complication arise was simply not 
acceptable. 
 
Although our data is insufficient and statistically not significant given the small sample size, 
the improved efficacy of EndoRings™-assisted colonoscopy may be implied if total numbers 
are taken into consideration. Overall more adenomas/polyps were found in the test arm of the 
study as compared to the control arm with no overall increase in procedure time or change in 
procedure experience. Some may even argue that operator experience with the EndoRings™ 
is superior to standard colonoscopy but whether this translates into a clinically significant, 
practice changing paradigm remains to be determined. 
 
2.5 Conclusion. 
In conclusion, this randomized cross-sectional study failed to demonstrate a statistically 
significant advantage in terms of ADR/PDR between EndoRings™ assisted colonoscopy and 
standard colonoscopy in patients with LS. Although there was a trend noticed favoring 
EndoRings™ assisted colonoscopy, no statistically significant conclusions could be reached, 
likely due to study limitations. EndoRings™ assisted colonoscopy was perceived as being 
advantageous in terms of improved total colonic visualisation and aiding in making 
interventions easier. The findings of comparable intubation times, withdrawal times, total 
procedure times and similar complication rates as standard colonoscopy are all in favour of 
EndoRings™ assisted colonoscopy. However, before any changes to clinical practice and/or 
surveillance programs are made these advantages need to be considered carefully as adopting 
new technologies places addition financial and logistical burden on already resource poor 
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systems, especially in our setting. However, having said that if future larger trials conducted 
in a more easily accessible population group (general population etc.) over a longer period 
prove EndoRings™ to be superior in detecting premalignant lesions then serious 
consideration to practice change would be validated if aiming to halt progression to cancer.
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Fig 2. Procedure time based on adequacy of bowel preparation. 
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 Fig 3. Number of polyps found in EndoRings™ arm VS standard colonoscopy arm. 
 
  
Fig 4. EndoRing™ on the tip of a colonoscope and in the colon [23].
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  Fig 5. Hypothetical Context 5 for power calculation. 
Context 5 
 
  Power Sample size 
1    50         <20 
2    60          25 
3    70          31 
4    80          39 





 Table 1: Procedure time in standard colonoscopy vs EndoRings™. 
 
 Standard Colonoscopy EndoRings™ 
N=27 each (Mean ± SD) (Mean ± SD) 
Time taken to reach 
caecum 
14.66 ± 8.35 14.42 ± 8.45 
Time taken to 
withdraw 
9.6 ± 4.72 9.46 ± 4.65 
Total procedure time 26.25 ± 12.34 25.9 ± 12.5 
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  Table 2: Number of polyps in standard colonoscopy vs EndoRings™. 
 
 Standard Colonoscopy EndoRings™ 
Number of Adenomas/Polyps (%) Number of 
People 
(%) Number of 
People 
0 66.67 18 62.96 17 
1 18.52 5 7.4 2 
2 3.7 1 14.8 4 
3 3.7 1 3.7 1 
4 3.7 1 3.7 1 
5 0 0 3.7 1 
10 3.7 1 0 0 
18 0 0 3.7 1 







Table 3: Number of polyps at different locations in standard colonoscopy vs EndoRings. 
 
 
 Standard Colonoscopy EndoRings™ 
Location of 
Adenomas/Polyps 
Number of times 
adenoma/polyp 
found in this location 
Number of times adenoma/polyp 
found in this location 
Caecum 4 5 
Ascending colon 1 3 
Transverse colon 4 5 
Descending colon 1 1 
Sigmoid colon 2 4 
Rectum 2 2 
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Table 4: Subgroup analysis (exclusion of individuals with previous colon resections). 
 
 No. of individuals in EndoRings™ 
assisted colonoscopy group (excluding 
those who had previous colectomies). 
N= 23 (27-4) 
No. of individuals in standard 
colonoscopy group (excluding those who 
had previous colectomies). 











0 4 11 5 8 
1 1 1 1 2 
2 0 3 0 0 
3 0 1 1 0 
4 0 1 0 0 
5 1 0 0 0 
Total 
Adenomas/Polyps 
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Appendix A: Supplementary data. 
Fig 1. Time (min.) to Caecum: EndoRings™ assisted colonoscopy VS standard colonoscopy. 
Fig 2. Time to Caecum probability plot for EndoRings™ arm. 
66 
Fig 3. Time to caecum: Probability plot for standard colonoscopy arm. 
Fig 4. Withdrawal time (minutes): EndoRings™ assisted colonoscopy VS standard 
colonoscopy. 
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Fig 5. Withdrawal time: Probability plot for EndoRings™ arm. 
68 
Fig 6. Withdrawal time: Probability plot for standard colonoscopy. 
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Appendix B: Ethics approval: 
Signature Removed
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Appendix C: Consent form (English): 
Consent Form to participate in medical research 
A randomized study of Endorings™ assisted vs standard 
colonoscopy for surveillance of at‐risk individuals with 
Lynch Syndrome 
Dr. R Dhar 
Supervisor 
Prof. PA Goldberg 
Department of Colorectal Surgery 
Groote Schuur Hospital 
Contact for research: Dr. R Dhar (Tel: +27 848866894; e-mail: 
rohindhar83@gmail.com) 
Contact for UCT Human Research Ethics Committee (Tel: +27 21 406 6346) 
I,  hereby agree to participate in the research project 
evaluating the use of Endorings™-assisted vs. Standard colonoscopy for detection of 
polyps in at risk individuals with Lynch Syndrome. The study will take place during the 
first week of September 2015, and I will be required to undergo one colonoscopy. The 
risks and benefits have been explained to me by Dr. R Dhar and Sr. Ursula Algar which I 
understand and have been given the opportunity to ask questions. 
I understand that my participation in this study is entirely voluntary. 
I understand there will not be any financial compensation involved for participation in 
this research. 
I agree to the use of my medical records which might include a physical examination. 







Consent form: Afrikaans. 
Toestemming tot deelname aan mediese 
navorsing 
Vergelyking tussen Endorings™‐geassisteerde kolonoskopie 
en konvensionele kolonoskopie in Lynch Sindroom pasiënte 
Dr. R Dhar 
Toesighouer 
Prof. PA Goldberg 
Departement van Kolorektale Chirurgie 
Groote Schuur Hospitaal 
Kontak persoon: Dr. R Dhar (Tel: +27 848866894; e-pos: rohindhar83@gmail.com) 
Kontak persoon, Menslike Novorsings Etiek Komitee (Tel: +27 21 406 6346) 
Ek,  gee hiermee toestemming tot deelname aan hierdie 
studie wat die gebruik van Endorings™ geassisteerde kolonoskopie met konvensionele 
kolonoskopie vergelyk. Die doel van beide Endorings™ geassisteerde- en konvensionele 
kolonoskopie is die identifikasie van kolon poliepe in individue met Lynch Sindroom. 
Hierdie studie vind plaas gedurende die eerste week van September 2015 en sluit een 
kolonoskopie ondersoek in. Die voordele asook die risiko’s verbonde aan hieride studie 
is deur Dr. R Dhar en Sr. Ursula Algar aan my verduidelik. Ek verstaan die risiko’s en 
voordele en was die geleentheid gebied om vrae te stel. 
Ek besef dat my deelname aan hierdie studie vrywillig is en dat daar geen finansiële 
kompensasie betrokke is nie. 
Ek stem saam met die gebruik van my mediese rekords wat kan insluit 'n fisiese 
ondersoek. Alle inligting sal as konfidensieel geag word. Dit kan ook in voordragte en 





Appendix D: Data sheet: 
 




Age   
Gender: O Female O Male 
Previous operations of the abdomen:    
First colonoscopy in his/her life: O Yes O No 
Field 2 
O use of  Endorings™ 
O without Endorings™ 
Field 3 
Bowel preparation: 
O Excellent (>90% of mucosa seen, mostly liquid colonic contents, minimal suctioning 
needed for adequate visualization) 
O Good (>90% of mucosa seen, mostly liquid colonic contents, significant suctioning 
needed for adequate visualization) 
O Fair (>90% of mucosa seen, mixture of liquid and semisolid colonic contents, which 
could be suctioned and/or washed) 
O Inadequate (<90% of mucosa seen, mixture of semisolid and solid colonic contents, 
which could not be suctioned or washed) 
Field 4 
O Complete colonoscopy 
- O with terminal ileum intubation 
- O without terminal ileum intubation 
O Partial colonoscopy (until  cm from anus) 
 
Field 5 
O No polyps detected during procedure 
O Polyps detected during procedure 
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Location/ size / number of polyps 
Cecum 
O Polyp Size <1cm, Number 
Ascending colon 
O Polyp Size <1cm, Number 
Hepatic flexure (right) 
O Polyp Size <1cm, Number 
Transvers colon 
O Polyp Size <1cm, Number 
Splenic flexure (left) 
O Polyp Size <1cm, Number 
Descending colon 
O Polyp Size <1cm, Number 
Sigmoid colon 
O Polyp Size <1cm, Number 
Rectum 
O Polyp Size <1cm, Number 
Field 6 
Caecum intubation time (min)   
Procedure time (min):   
O Polyp size >1cm, Number 
O Polyp size >1cm, Number 
O Polyp size >1cm, Number 
O Polyp size >1cm, Number 
O Polyp size >1cm, Number 
O Polyp size >1cm, Number 
O Polyp size >1cm, Number 
O Polyp size >1cm, Number 
Withdrawal time (min) (stopwatch is paused for procedures like: suction, biopsy, 
polypectomy):   




Analgesia: Type (mg) 
O yes O perforation, O mucosa-laceration, O bleeding, O loss of Endorings™ 
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Appendix E: Power Calculation Scenarios 
 
  Power Analysis Summary 
Objective Perform a power calculation (sampling unit = colon) to compare the average 
number of polyps per colon in arms one and two. 
Inputs: 
• Arm 1 – 10 polyps in 50 colons, 15 -20 polyps in 50 colons (50% -
100% increase) 
• To get a sense of variability – about 90% of colons have 0 polyps, of 
the remaining 10%, about 80% have 1 polyp, 10% have 2… 
Approach Perform a power calculation based on a z-test 
• Data is highly non-normal, therefore rely on approximate normality of 
mean (large sample theory) 
• Based on inputs above, try to get a sense of reasonable inputs for 
variability 
The data is highly right-skewed (will have a large variance), so we cannot 
expect much power in a comparison of means. 
Software R (64 bit, version 3.1.3) 
Report version v1.0 
Data file NA 





  Six hypothetical contexts were considered 
 Number of polyps per 50 colons  Coefficient of variation (ratio of standard 
deviation to mean) for number of polyps 
per colon 
Arm 1 Arm2 
1 10 15 50% 
2 10 15 100% 
3 10 15 200% 
4 10 20 50% 
5 10 20 100% 






Context 1 Context 4 
 
  Power Sample size 
1    50         <20 
2    60         <20 
3    70          20 
4    80          26 
5    90          34 
 
  Power Sample size 
1    50         <20 
2    60         <20 
3    70         <20 
4    80         <20 
5    90         <20 
Context 2 Context 5 
 
  Power Sample size 
1    50          50 
2    60          64 
3    70          80 
4    80         102 
5    90         137 
 
  Power Sample size 
1    50         <20 
2    60          25 
3    70          31 
4    80          39 
5    90          53 
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Context 3 Context 6 
  Power Sample size 
1    50    200 
2    60    >200
  Power Sample size 
1    50     77 
2    60     98 
3    70    123 
4    80    157 
5    90    >200
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Appendix F: Instruction to Authors 
International Journal of Colorectal Disease 
Text Formatting 
Manuscripts should be submitted in Word. 
• Use a normal, plain font (e.g., 10-point Times Roman) for text.
• Use italics for emphasis.
• Use the automatic page numbering function to number the pages.
• Do not use field functions.
• Use tab stops or other commands for indents, not the space bar.
• Use the table function, not spreadsheets, to make tables.
• Use the equation editor or MathType for equations.
• Save your file in docx format (Word 2007 or higher) or doc format (older Word
versions).
Headings 
Please use no more than three levels of displayed headings. 
Abbreviations 
Abbreviations should be defined at first mention and used consistently thereafter. 
References 
Citation 
Reference citations in the text should be identified by numbers in square brackets. Some 
examples: 
1. Negotiation research spans many disciplines [3].
2. This result was later contradicted by Becker and Seligman [5].
3. This effect has been widely studied [1-3, 7].
78 
Reference list 
The list of references should only include works that are cited in the text and that have been 
published or accepted for publication. Personal communications and unpublished works 
should only be mentioned in the text. Do not use footnotes or endnotes as a substitute for a 
reference list. 
The entries in the list should be numbered consecutively. 
• Journal article
Gamelin FX, Baquet G, Berthoin S, Thevenet D, Nourry C, Nottin S, Bosquet L 
(2009) Effect of high intensity intermittent training on heart rate variability in 
prepubescent children. Eur J Appl Physiol 105:731-738. 
https://doi.org/10.1007/s00421-008-0955-8 
Ideally, the names of all authors should be provided, but the usage of “et al” in long 
author lists will also be accepted: 
Smith J, Jones M Jr, Houghton L et al (1999) Future of health insurance. N Engl J 
Med 965:325–329 
• Online document
Cartwright J (2007) Big stars have weather too. IOP Publishing PhysicsWeb. 
http://physicsweb.org/articles/news/11/6/16/1. Accessed 26 June 2007 
Always use the standard abbreviation of a journal’s name according to the ISSN List of Title 
Word Abbreviations 
Tables 
• All tables are to be numbered using Arabic numerals.
• Tables should always be cited in text in consecutive numerical order.
• For each table, please supply a table caption (title) explaining the components of the
table.
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• Identify any previously published material by giving the original source in the form of 
a reference at the end of the table caption. 
• Footnotes to tables should be indicated by superscript lower-case letters (or asterisks 




• To add lettering, it is best to use Helvetica or Arial (sans serif fonts). 
• Keep lettering consistently sized throughout your final-sized artwork, usually about 
2–3 mm (8–12 pt). 
• Variance of type size within an illustration should be minimal, e.g., do not use 8-pt 
type on an axis and 20-pt type for the axis label. 
• Avoid effects such as shading, outline letters, etc. 
• Do not include titles or captions within your illustrations. 
• All figures are to be numbered using Arabic numerals. 
• Figures should always be cited in text in consecutive numerical order. 
• Figure parts should be denoted by lowercase letters (a, b, c, etc.). 
• If an appendix appears in your article and it contains one or more figures, continue the 
consecutive numbering of the main text. Do not number the appendix figures, "A1, 
A2, A3, etc." Figures in online appendices (Electronic Supplementary Material) 
should, however, be numbered separately. 
• Each figure should have a concise caption describing accurately what the figure 
depicts. Include the captions in the text file of the manuscript, not in the figure file. 
• Figure captions begin with the term Fig. in bold type, followed by the figure number, 
also in bold type. 
• No punctuation is to be included after the number, nor is any punctuation to be placed 
at the end of the caption. 
• Identify all elements found in the figure in the figure caption; and use boxes, circles, 
etc., as coordinate points in graphs. 
• Identify previously published material by giving the original source in the form of a 
reference citation at the end of the figure caption. 
• Figures should be submitted separately from the text, if possible. 
• When preparing your figures, size figures to fit in the column width. 
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Informed consent 
The following statement should be included: 
Informed consent: “Informed consent was obtained from all individual participants 
included in the study.” 
If identifying information about participants is available in the article, the following 
statement should be included: 
“Additional informed consent was obtained from all individual participants for whom 
identifying information is included in this article.” 
